Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study - Budde, LE; Sehn, LH; Matasar, M (Lancet Oncol, 2022)